NMD4C Hire New Communications Coordinator
New Communications Coordinator
The NMD4C are pleased to announce the hiring of their new communications coordinator, James Davis.
James holds a Masters degree in Human Kinetics, and holds previous network creation experience. Through his efforts to help build a national Sport Safety framework, James has a skillset well-suited to the role. He also has research experience from his time at Cochrane. While there he worked on systematic reviews of literature to aid in health policy development.
Communications Coordinator Role
As one of two dedicated NMD4C staff members, James writes and coordinates all network communications. This includes news updates, monthly newsletter, website, and social media (Twitter, Facebook, and LinkedIn). He also manages membership and will liaise with the many people and sites involved in the network.
Contact James
If you are looking for more information, check out James’ bio! Here you can find his contact information. If you have any communications-related inquiries, please send James a message!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.